MICA and cervical cancer: In particular, MICA-A5.1 homozygotes had a 1.84-fold increased risk of developing cervical cancer (OR = 1.84, 95% CI = 1.46–2.32; P = 3.2 × 10−7), whereas MICA-A5 homozygotes had nearly threefold protection against cervical cancer (OR = 0.34, 95% CI = 0.16–0.75; P = 7.0×10−3) as compared to noncarriers, respectively.